Zeria Pharmaceutical's Attributable Profit Climbs 12% in Fiscal H1

MT NewswiresNov 22 06:04 ET

Zeria Pharmaceutical: Confirmation letter

EDINETNov 7 20:01 ET · Announcements

Zeria Pharmaceutical: Half-Year Report - Term 71 (2024/04/01 - 2025/03/31)

EDINETNov 7 20:00 ET · Announcements

JFE revises down to 160 billion yen from 260 billion yen for the third quarter.

JFE <5411> announced a revision to the financial estimates for the fiscal year ending March 2025. The sales revenue was revised downward from 5 trillion 240 billion yen to 4 trillion 970 billion yen, and the operating profit was revised downward from 260 billion yen to 160 billion yen. In the iron & steel business, due to the rise in construction costs in the domestic building materials sector and labor shortages, further demand deceleration is expected, as well as stagnation in demand for Asia-bound steel for automobiles, resulting in a standalone crude steel production volume of around 22.4 million tons, which is 0.6 million tons lower than the previous outlook. [Positive Rating] <9001>

Fisco JapanNov 6 15:52 ET

Zeria Pharmaceutical Reports Strong Mid-Year Growth

TipRanksNov 6 02:29 ET

Zeria Pharmaceutical: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [Japanese GAAP] (consolidated)

JPXNov 6 02:00 ET · Announcements